Reward: The risk of ruining your research is not worth the minimal cost of a new vial
After decades with no disease-modifying drug, 20242026 finally delivered the first targeted therapies: Novartis ianalumab met both NEPTUNUS-1 & NEPTUNUS-2 Phase 3 endpoints and won FDA Breakthrough Therapy status in Jan 2026, and J&Js nipocalimab was positive in the Phase 2 DAHLIAS trial ( The Lancet )
For example, those with oily skin may benefit from lightweight, oil-free moisturizers, while those with dry skin might need richer creams that provide adequate hydration
Most people do not have a problem obtaining the RDA of 2.4 g/day of vitamin B 12 from food
Curcumin, the active ingredient in turmeric, may have benefits for multiple inflammatory conditions, including migraine
He likened the risk to Russian roulette but added: "It's more like using a machine gun than a pistol." The Medicines and Healthcare products Regulatory Agency says it has spent 10 years targeting melanotan products
